The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders

Michael L Sulkowski, Daniel A. Geller, Adam B. Lewin, Tanya K. Murphy, Andrew Mittelman, Ashley Brown, Eric A. Storch

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are needed to adequately treat non- and partial-responders. Emerging research suggests that interventions that augment learning and memory processes associated with exposure therapy (i.e., extinction training) may display promise in enhancing treatment response in OCRDs. As the most studied example, d-cycloserine (DCS) is a relatively safe cognitive enhancer that appears to accelerate treatment gains associated with exposure therapy. This article reviews research on the use of DCS and other putative cognitive modifiers as they relate to the treatment (or prospective treatment) of obsessive-compulsive disorder and other OCRDs.

Original languageEnglish (US)
Pages (from-to)317-324
Number of pages8
JournalCurrent Psychiatry Reviews
Volume10
Issue number4
StatePublished - Jan 1 2014

Fingerprint

Implosive Therapy
Cycloserine
Obsessive-Compulsive Disorder
Nootropic Agents
Therapeutics
Research
Learning

Keywords

  • Brain-derived neurotrophic factor
  • Cognitive enhancer
  • D-cycloserine
  • Glucocorticoids
  • Memory reconsolidation
  • Obsessive-compulsive disorder
  • Yohimbine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Sulkowski, M. L., Geller, D. A., Lewin, A. B., Murphy, T. K., Mittelman, A., Brown, A., & Storch, E. A. (2014). The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders. Current Psychiatry Reviews, 10(4), 317-324.

The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders. / Sulkowski, Michael L; Geller, Daniel A.; Lewin, Adam B.; Murphy, Tanya K.; Mittelman, Andrew; Brown, Ashley; Storch, Eric A.

In: Current Psychiatry Reviews, Vol. 10, No. 4, 01.01.2014, p. 317-324.

Research output: Contribution to journalArticle

Sulkowski, ML, Geller, DA, Lewin, AB, Murphy, TK, Mittelman, A, Brown, A & Storch, EA 2014, 'The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders', Current Psychiatry Reviews, vol. 10, no. 4, pp. 317-324.
Sulkowski, Michael L ; Geller, Daniel A. ; Lewin, Adam B. ; Murphy, Tanya K. ; Mittelman, Andrew ; Brown, Ashley ; Storch, Eric A. / The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders. In: Current Psychiatry Reviews. 2014 ; Vol. 10, No. 4. pp. 317-324.
@article{c53e8bc42bbc4727a9813b4eb5a0a8ba,
title = "The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders",
abstract = "Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are needed to adequately treat non- and partial-responders. Emerging research suggests that interventions that augment learning and memory processes associated with exposure therapy (i.e., extinction training) may display promise in enhancing treatment response in OCRDs. As the most studied example, d-cycloserine (DCS) is a relatively safe cognitive enhancer that appears to accelerate treatment gains associated with exposure therapy. This article reviews research on the use of DCS and other putative cognitive modifiers as they relate to the treatment (or prospective treatment) of obsessive-compulsive disorder and other OCRDs.",
keywords = "Brain-derived neurotrophic factor, Cognitive enhancer, D-cycloserine, Glucocorticoids, Memory reconsolidation, Obsessive-compulsive disorder, Yohimbine",
author = "Sulkowski, {Michael L} and Geller, {Daniel A.} and Lewin, {Adam B.} and Murphy, {Tanya K.} and Andrew Mittelman and Ashley Brown and Storch, {Eric A.}",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
volume = "10",
pages = "317--324",
journal = "Current Psychiatry Reviews",
issn = "1573-4005",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders

AU - Sulkowski, Michael L

AU - Geller, Daniel A.

AU - Lewin, Adam B.

AU - Murphy, Tanya K.

AU - Mittelman, Andrew

AU - Brown, Ashley

AU - Storch, Eric A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are needed to adequately treat non- and partial-responders. Emerging research suggests that interventions that augment learning and memory processes associated with exposure therapy (i.e., extinction training) may display promise in enhancing treatment response in OCRDs. As the most studied example, d-cycloserine (DCS) is a relatively safe cognitive enhancer that appears to accelerate treatment gains associated with exposure therapy. This article reviews research on the use of DCS and other putative cognitive modifiers as they relate to the treatment (or prospective treatment) of obsessive-compulsive disorder and other OCRDs.

AB - Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are needed to adequately treat non- and partial-responders. Emerging research suggests that interventions that augment learning and memory processes associated with exposure therapy (i.e., extinction training) may display promise in enhancing treatment response in OCRDs. As the most studied example, d-cycloserine (DCS) is a relatively safe cognitive enhancer that appears to accelerate treatment gains associated with exposure therapy. This article reviews research on the use of DCS and other putative cognitive modifiers as they relate to the treatment (or prospective treatment) of obsessive-compulsive disorder and other OCRDs.

KW - Brain-derived neurotrophic factor

KW - Cognitive enhancer

KW - D-cycloserine

KW - Glucocorticoids

KW - Memory reconsolidation

KW - Obsessive-compulsive disorder

KW - Yohimbine

UR - http://www.scopus.com/inward/record.url?scp=84926348580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926348580&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84926348580

VL - 10

SP - 317

EP - 324

JO - Current Psychiatry Reviews

JF - Current Psychiatry Reviews

SN - 1573-4005

IS - 4

ER -